Processing

Please wait...

Settings

Settings

1. WO2020003213 - METHODS OF DIAGNOSING AND TREATING CANCER PATIENTS EXPRESSING HIGH LEVELS OF TGF-B RESPONSE SIGNATURE

Publication Number WO/2020/003213
Publication Date 02.01.2020
International Application No. PCT/IB2019/055475
International Filing Date 27.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
444
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
[IPC code unknown for C12Q 1/6886]
A61K 31/444 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)
C12Q 1/6886 (2018.01)
CPC
A61K 31/444
A61P 35/00
C12Q 1/6886
C12Q 2600/158
Applicants
  • MEDPACTO, INC. [KR/KR]; 145 Gwanggyo-ro AICT Building C, 5F, Room 506, Suwon-si, Gyeonggi-do 16229, KR
Inventors
  • OCK, Chan-young; KR
  • KIM, Seong Jin; KR
Priority Data
62/690,56727.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF DIAGNOSING AND TREATING CANCER PATIENTS EXPRESSING HIGH LEVELS OF TGF-B RESPONSE SIGNATURE
(FR) MÉTHODES DE DIAGNOSTIC ET DE TRAITEMENT DE PATIENTS ATTEINTS D'UN CANCER EXPRIMANT DES NIVEAUX ÉLEVÉS DE SIGNATURE DE RÉPONSE AU TGF-B
Abstract
(EN)
The present invention relates to methods for treating colorectal cancer patients comprising selecting patients who express high level of the TGF-β response signatures and co-administering TGF-β inhibitor with human immunoglobulin. The invention also relates to the method of diagnosing and selecting patients which is likely to benefit from the treatment comprising the determination of the gene expression levels of TGF-β response signature by analyzing histopathologic images of stroma or RNA sequence from the patients.
(FR)
La présente invention concerne des méthodes de traitement de patients atteints d'un cancer colorectal comprenant la sélection de patients qui expriment un niveau élevé des signatures de réponse au TGF-β et l'administration conjointe d'un inhibiteur de TGF-β avec l'immunoglobuline humaine. L'invention concerne également la méthode de diagnostic et de sélection de patients qui sont susceptibles de bénéficier du traitement comprenant la détermination des niveaux d'expression génique de la signature de réponse au TGF-β par l'analyse d'images histopathologiques de stroma ou de séquence d'ARN provenant des patients.
Latest bibliographic data on file with the International Bureau